Jazz Pharmaceuticals stock expands epilepsy pipeline after Actio deal

Published on 10/04/2026 at 22:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Jazz Pharmaceuticals stock gains a new epilepsy asset after the USD 820 million Actio deal closed September 15, 2026. Q2 revenue rose 15.5 percent.

JAZZ, IE00B4Q5ZN47, Illustration mit AI erstellt.

Jazz Pharmaceuticals plc (ISIN IE00B4Q5ZN47) completed its Actio Biosciences acquisition for USD 820 million upfront on September 15, 2026. The transaction adds ABS-1230, a clinical-stage precision therapy for KCNT1-related epilepsy, according to Jazz Pharmaceuticals.

Actio adds a rare epilepsy asset

Actio is now a wholly owned Jazz subsidiary, and ABS-1230 is designed as an orally available KCNT1 inhibitor. The deal gives Jazz a new clinical-stage program in epilepsy while extending a portfolio that already includes Xywav, Epidiolex and other neuroscience products.

The acquisition is also a test of capital allocation. Jazz funded a large pipeline transaction after reporting record second-quarter revenue, so the commercial performance of its existing brands remains central to the investment case.

Revenue rises while EPS misses

Jazz generated USD 1.21 billion of revenue in Q2 2026, up 15.5 percent from the same quarter a year earlier. MarketBeat reported that quarterly EPS was USD 5.71 against a USD 6.18 consensus estimate, a USD 0.47 miss.

The split between revenue and earnings is important. Sales exceeded the USD 1.11 billion estimate, but the earnings shortfall shows that portfolio growth alone does not determine near-term valuation. Jazz also reported USD 192.9 million of consolidated net income for Q2 2026.

Consensus stays above the market price

According to Stock Analysis, 22 analysts carry an average Buy rating and a 12-month price target of USD 294.27. The target stands 24.87 percent above the October 2 price of USD 235.67, while the published high target is USD 337.00.

Jazz Pharmaceuticals stock stays below its yearly high

Jazz Pharmaceuticals stock closed at USD 235.67 on Nasdaq on October 2, 2026, up 1.14 percent from the prior close. The price remained 11.53 percent below the 52-week high of USD 266.38, with the 52-week low at USD 128.80.